Profarma (B3: PFRM3) revenue
Profarma reported revenue of BRL 11,451m for fiscal 2025, 12.8% more than in fiscal 2024 (BRL 10,154m). Since fiscal 2016 its revenue has grown by 180.3%, an average growth of 12.1% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | BRL 11,451m | +12.8% | BRL 350.0m | 3.1% |
| 2024 | BRL 10,154m | +17.2% | BRL 299.7m | 3.0% |
| 2023 | BRL 8,662m | +10.8% | BRL 261.1m | 3.0% |
| 2022 | BRL 7,816m | +21.9% | BRL 242.9m | 3.1% |
| 2021 | BRL 6,413m | +17.0% | BRL 130.7m | 2.0% |
| 2020 | BRL 5,481m | +14.2% | BRL 120.6m | 2.2% |
| 2019 | BRL 4,801m | +12.4% | BRL 60.9m | 1.3% |
| 2018 | BRL 4,271m | +4.2% | BRL 54.9m | 1.3% |
| 2017 | BRL 4,101m | +0.4% | −BRL 11.3m | −0.3% |
| 2016 | BRL 4,085m | — | BRL 76.2m | 1.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of Brazilian reais, except per-share amounts.
Questions about the revenue of Profarma
- How much revenue did Profarma make in fiscal 2025?
- Profarma reported revenue of BRL 11,451m for fiscal 2025, compared with BRL 10,154m in fiscal 2024.
- How much has the revenue of Profarma grown?
- Between fiscal 2016 and fiscal 2025 it went from BRL 4,085m to BRL 11,451m: 180.3% more, an average growth of 12.1% a year.
- What was the best year for revenue at Profarma?
- Of its last 10 fiscal years, fiscal 2025, with BRL 11,451m.
- Where do the figures for Profarma come from?
- From the annual financial statements (DFP) that Profarma files with the CVM, the Brazilian securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual financial statements (DFP) that Profarma files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Profarma: the Profarma page · annual accounts · net income · dividends paid.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.